Tydén Gunnar, Kumlien Gunilla, Fehrman Ingela
Department of Transplantation Surgery, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden.
Transplantation. 2003 Aug 27;76(4):730-1. doi: 10.1097/01.TP.0000078622.43689.D4.
Historically, ABO-incompatible kidney transplantations have only been undertaken after splenectomy and unspecific plasmapheresis and with quadruple drug immunosuppression plus B-cell specific drugs. We have evaluated a protocol for ABO-incompatible kidney transplantation without splenectomy using antigen-specific immunoadsorption, rituximab, and a conventional triple-drug immunosuppressive regimen.
The protocol called for a 10-day pretransplant conditioning period starting with one dosage of rituximab and followed by full dose tacrolimus, mycophenolate mofetil, and prednisolone. Antigen-specific immunoadsorption was performed on pretransplant days -6, -5, -4, and -1. After the last session, 0.5 g/kg of intravenous immunoglobulin was administered. Postoperatively, three more apheresis sessions were given every third day. Furthermore, if there was a significant increase in the antibody titers, extra sessions were considered.
Four patients have received transplants with this protocol. The donor-recipient blood groups were A2/O, B/O, B/A, and A1/O. The ABO-antibodies were readily removed by the antigen-specific immunoadsorption and were kept at a low level posttransplantation by further adsorptions. There were no side effects, and all patients have normal renal-transplant function.
We conclude that after one infusion each of rituximab and intravenous immunoglobulin and antigen-specific immunoadsorption, blood-group-incompatible renal transplantations can be performed with standard immunosuppression and without splenectomy.
从历史上看,ABO血型不相容的肾移植仅在脾切除和非特异性血浆置换后进行,并采用四联药物免疫抑制加B细胞特异性药物。我们评估了一种不进行脾切除的ABO血型不相容肾移植方案,该方案使用抗原特异性免疫吸附、利妥昔单抗和传统的三联药物免疫抑制方案。
该方案要求在移植前进行为期10天的预处理,开始时使用一剂利妥昔单抗,然后是全剂量的他克莫司、霉酚酸酯和泼尼松龙。在移植前第-6、-5、-4和-1天进行抗原特异性免疫吸附。在最后一次治疗后,给予0.5g/kg的静脉注射免疫球蛋白。术后,每三天再进行三次血液分离治疗。此外,如果抗体滴度显著升高,则考虑增加治疗次数。
四名患者按照该方案接受了移植。供受者血型为A2/O、B/O、B/A和A1/O。ABO抗体通过抗原特异性免疫吸附很容易被清除,并在移植后通过进一步吸附保持在低水平。没有副作用,所有患者的肾移植功能均正常。
我们得出结论,在分别输注一次利妥昔单抗、静脉注射免疫球蛋白和进行抗原特异性免疫吸附后,ABO血型不相容的肾移植可以在标准免疫抑制下且不进行脾切除的情况下进行。